Oral Administration of Limosilactobacillus reuteri KBL346 Ameliorates Influenza Virus A/PR8 Infection in Mouse

• DOI: 10.1007/s12602-024-10301-8
• Publication Date: 2024-07-01T13:02:13Z
• Authors: Doseon Choi; Sung Jae Jang; Sueun Choi; SungJun Park; Woon-Ki Kim; Giljae Lee; Cheonghoon Lee; GwangPyo Ko
• Keywords: Lactobacillus reuteri

Abstract Influenza virus infection is an important public-health concern because of its high transmissibility and potential for severe complications. To mitigate the severity complications influenza, probiotics containing Lactobacillus are used generally recognized as safe. We evaluated anti-influenza effect Limosilactobacillus reuteri ( L. ) KBL346, isolated from fecel sample healthy South Koreans, in mice. BALB/c mice were orally administered live heat-inactivated KBL346. After with influenza (A/Puerto Rico/8/34) 0.5 times 50% lethal dose (LD 50 ), body weight loss was improved recovery accelerated. Furthermore, KBL346 survival rate infected 4 LD virus. Heat-inactivated reduced viral titer lung plasma immunoglobulin G level. Expression levels genes encoding inflammatory cytokines, such interferon-γ toll-like receptor 2 Tlr2 decreased tissues Live increased expression level Adamts4 , which promotes after infection, that . The α-diversity gut microbiome modulated by administration In addition, structure microbial community differed according to degree loss. has alleviate disease improve histopathological changes A/PR8, suggesting efficacy a probiotic against infection.